Jun 12, 2023 / 03:00PM GMT
Robert Ang - Vor Biopharma, Inc. - President and CEO
Yeah, sure. So Vor is a cell therapy company. We're a little bit different to other companies. We actually focus on engineering hematopoietic stem cells. So these are the cells that populate your blood system, live in the bone marrow that give rise to cancer.
Now, of course, bone marrow transplantation has been the standard of care for many years. Unfortunately, even with a transplant, a lot of patients with cancer still relapse very quickly. So the whole premise behind Vor is to create next-generation stem cell transplants that are resistant to targeted therapies, and we use genome engineering to do that. So by manipulating the genome of these stem cells that we're using as the next-gen transplant, we're hoping that we can we open up a whole universe of treatment opportunities for patients.
Questions and Answers:
Andrea Tan - Goldman Sachs - Analyst(technical difficulty) on Friday of you lead program (technical difficulty) or high risk (technical difficulty) maybe walk us through (technical
Trustpilot
